指南与共识肺血管病与心包/心肌炎血脂与心血管预防

2021年主动脉与外周动脉疾病抗血栓治疗共识解读

Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy.
指南 / 共识 · Eur Heart J · 2021-01-01

该共识由ESC主动脉与外周血管疾病工作组、血栓工作组和心血管药物治疗工作组联合制定,旨在更新主动脉和/或外周动脉疾病患者的最佳抗血栓策略。若无慢性口服抗凝的特定适应症,单一抗血小板药物是长期抗血栓治疗的基础;根据缺血与出血风险及治疗路径(如腔内治疗),可考虑联合另一抗血小板药或低剂量抗凝药。共识按动脉病变部位和临床表现提供抗血栓指导,但不能替代多学科团队讨论。

要点

  • 无慢性口服抗凝适应症时,单一抗血小板药是主动脉或外周动脉疾病长期抗血栓治疗的基础。
  • 根据患者缺血与出血风险及治疗路径(如腔内治疗),可考虑联合另一抗血小板药或低剂量抗凝药。
  • 抗血栓治疗需定期重新评估,因缺血/出血平衡随时间变化;多学科团队讨论在平衡不确定时尤为重要。

核心结论

  • 在无慢性口服抗凝特定适应症时,单一抗血小板药物是主动脉或外周动脉疾病患者长期抗血栓治疗的基础。
  • 根据缺血与出血风险及治疗路径(如腔内治疗),可考虑联合另一抗血小板药或低剂量抗凝药。

研究设计与样本

  • 由ESC主动脉与外周血管疾病工作组、血栓工作组和心血管药物治疗工作组联合制定的共识文件。

主要发现

  • 主动脉或外周动脉疾病患者的抗血栓治疗试验数量远少于冠心病患者,但近期证据值得纳入临床实践。

关键数值与推荐

  • 单一抗血小板药物作为长期抗血栓治疗的基础(无慢性口服抗凝特定适应症时)。
  • 联合另一抗血小板药或低剂量抗凝药需基于患者缺血与出血风险及治疗路径(如腔内治疗)考虑。

临床怎么用

  • 根据动脉疾病定位和临床表现,参考共识指导抗血栓治疗。
  • 定期重新评估抗血栓治疗,因缺血/出血平衡随时间变化。
  • 在缺血/出血平衡不确定的患者中,多学科团队讨论尤为重要。

局限性

  • 共识不能替代多学科团队讨论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this collaborative document is to provide an update for clinicians on best antithrombotic strategies in patients with aortic and/or peripheral arterial diseases. Antithrombotic therapy is a pillar of optimal medical treatment for these patients at very high cardiovascular risk. While the number of trials on antithrombotic therapies in patients with aortic or peripheral arterial diseases is substantially smaller than for those with coronary artery disease, recent evidence deserves to be incorporated into clinical practice. In the absence of specific indications for chronic oral anticoagulation due to concomitant cardiovascular disease, a single antiplatelet agent is the basis for long-term antithrombotic treatment in patients with aortic or peripheral arterial diseases. Its association with another antiplatelet agent or low-dose anticoagulants will be discussed, based on patient's ischaemic and bleeding risk as well therapeutic paths (e.g. endovascular therapy). This consensus document aims to provide a guidance for antithrombotic therapy according to arterial disease localizations and clinical presentation. However, it cannot substitute multidisciplinary team discussions, which are particularly important in patients with uncertain ischaemic/bleeding balance. Importantly, since this balance evolves over time in an individual patient, a regular reassessment of the antithrombotic therapy is of paramount importance.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Aboyans V, Bauersachs R, Mazzolai L, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021. PMID: 34279602. doi:10.1093/eurheartj/ehab390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。